Pillstats
Rx only · Gel · Topical

Podofilox

Brands: Condylox · Podofilox

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCD06BB04
RxCUI (US)8463
US makers2 labelers
Packages2
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$49.45$98.90$148.35$197.80Aug 2025Mar 2026Jul 2026
$148.045
Latest avg · Jul 22, 2026
-14%
Since Aug 20, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

5891.2K1.8K2.4K2025 Q12025 Q22025 Q32025 Q42026 Q1
640
Rx · 2026 Q1
2.1K
Units dispensed
-59%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 1 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Padagis US LLCunknown1SUPPLYING
Allergan, Inc.unknown1EXITED 2026

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jan 28, 2026
    RESOLVEDShortage resolved: Podofilox Topical Gel (AbbVie Inc.)

    Podofilox Topical Gel — reported in shortage by AbbVie Inc.. Therapeutic category: Dermatology, Other.

  • Jan 28, 2026
    SHORTAGEDrug shortage: Podofilox Topical Gel (AbbVie Inc.)

    Podofilox Topical Gel — reported in shortage by AbbVie Inc.. Therapeutic category: Dermatology, Other.